A novel event-free survival endpoint in locally advanced pancreatic cancer

The treatment paradigm for locally advanced pancreatic cancer (LAPC) is evolving rapidly. The development of neoadjuvant therapies composed of combination therapies and the evaluation of their impact on conversion to borderline resectable (BR) status, resection, and ultimately overall survival (OS)...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Pascal Hammel, Ewa Carrier, Mairead Carney, Mark Eisner, Thomas Fleming
Formato:	article
Lenguaje:	EN
Publicado:	SAGE Publishing 2021
Materias:	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/40c80974de284a6c9e33fe3074c7496e
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:40c80974de284a6c9e33fe3074c7496e
record_format	dspace
spelling	oai:doaj.org-article:40c80974de284a6c9e33fe3074c7496e2021-12-01T23:33:33ZA novel event-free survival endpoint in locally advanced pancreatic cancer1758-835910.1177/17588359211059586https://doaj.org/article/40c80974de284a6c9e33fe3074c7496e2021-11-01T00:00:00Zhttps://doi.org/10.1177/17588359211059586https://doaj.org/toc/1758-8359The treatment paradigm for locally advanced pancreatic cancer (LAPC) is evolving rapidly. The development of neoadjuvant therapies composed of combination therapies and the evaluation of their impact on conversion to borderline resectable (BR) status, resection, and ultimately overall survival (OS) are presently being pursued. These efforts justify re-visiting study endpoints in order to better predict therapeutic effects on OS, by capturing not only the achievement of R0 resection at the end of induction therapy but also the long-term reductions in the rate of local and distal recurrence. The proposed herein event-free survival (EFS) endpoint, with its novel definition specific to LAPC, is formulated to achieve these objectives. It is an analog to disease-free survival (DFS) endpoint in the adjuvant setting applied to the neoadjuvant setting and may be a valuable surrogate endpoint for this patient population.Pascal HammelEwa CarrierMairead CarneyMark EisnerThomas FlemingSAGE PublishingarticleNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENTherapeutic Advances in Medical Oncology, Vol 13 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Pascal Hammel Ewa Carrier Mairead Carney Mark Eisner Thomas Fleming A novel event-free survival endpoint in locally advanced pancreatic cancer
description	The treatment paradigm for locally advanced pancreatic cancer (LAPC) is evolving rapidly. The development of neoadjuvant therapies composed of combination therapies and the evaluation of their impact on conversion to borderline resectable (BR) status, resection, and ultimately overall survival (OS) are presently being pursued. These efforts justify re-visiting study endpoints in order to better predict therapeutic effects on OS, by capturing not only the achievement of R0 resection at the end of induction therapy but also the long-term reductions in the rate of local and distal recurrence. The proposed herein event-free survival (EFS) endpoint, with its novel definition specific to LAPC, is formulated to achieve these objectives. It is an analog to disease-free survival (DFS) endpoint in the adjuvant setting applied to the neoadjuvant setting and may be a valuable surrogate endpoint for this patient population.
format	article
author	Pascal Hammel Ewa Carrier Mairead Carney Mark Eisner Thomas Fleming
author_facet	Pascal Hammel Ewa Carrier Mairead Carney Mark Eisner Thomas Fleming
author_sort	Pascal Hammel
title	A novel event-free survival endpoint in locally advanced pancreatic cancer
title_short	A novel event-free survival endpoint in locally advanced pancreatic cancer
title_full	A novel event-free survival endpoint in locally advanced pancreatic cancer
title_fullStr	A novel event-free survival endpoint in locally advanced pancreatic cancer
title_full_unstemmed	A novel event-free survival endpoint in locally advanced pancreatic cancer
title_sort	novel event-free survival endpoint in locally advanced pancreatic cancer
publisher	SAGE Publishing
publishDate	2021
url	https://doaj.org/article/40c80974de284a6c9e33fe3074c7496e
work_keys_str_mv	AT pascalhammel anoveleventfreesurvivalendpointinlocallyadvancedpancreaticcancer AT ewacarrier anoveleventfreesurvivalendpointinlocallyadvancedpancreaticcancer AT maireadcarney anoveleventfreesurvivalendpointinlocallyadvancedpancreaticcancer AT markeisner anoveleventfreesurvivalendpointinlocallyadvancedpancreaticcancer AT thomasfleming anoveleventfreesurvivalendpointinlocallyadvancedpancreaticcancer AT pascalhammel noveleventfreesurvivalendpointinlocallyadvancedpancreaticcancer AT ewacarrier noveleventfreesurvivalendpointinlocallyadvancedpancreaticcancer AT maireadcarney noveleventfreesurvivalendpointinlocallyadvancedpancreaticcancer AT markeisner noveleventfreesurvivalendpointinlocallyadvancedpancreaticcancer AT thomasfleming noveleventfreesurvivalendpointinlocallyadvancedpancreaticcancer
_version_	1718403979308695552

A novel event-free survival endpoint in locally advanced pancreatic cancer

Ejemplares similares